199 related articles for article (PubMed ID: 25775920)
1. The Role of Regulatory Agencies and Intellectual Property: Part II.
Noonan KE
Cold Spring Harb Perspect Med; 2015 Mar; 5(7):a020834. PubMed ID: 25775920
[TBL] [Abstract][Full Text] [Related]
2. Unsettling drug patent settlements: a framework for presumptive illegality.
Carrier MA
Mich Law Rev; 2009 Oct; 108(1):37-80. PubMed ID: 20535881
[TBL] [Abstract][Full Text] [Related]
3. Antitrust issues in the settlement of pharmaceutical patent disputes, Part II.
Leary TB
J Health Law; 2001; 34(4):657-71. PubMed ID: 11833411
[TBL] [Abstract][Full Text] [Related]
4. Pharmaceutical patent settlements: the antitrust risks.
Balto DA
Food Drug Law J; 2000; 55(3):321-41. PubMed ID: 11824464
[No Abstract] [Full Text] [Related]
5. The wake of FTC v. Actavis: practical implications on the pharmaceutical industry.
Ritter M; Tempesta J; Ragusa P
Pharm Pat Anal; 2014 Jul; 3(4):345-7. PubMed ID: 25291307
[No Abstract] [Full Text] [Related]
6. Reanalyzing reverse payment settlements: a solution to the patentee's dilemma.
Wang Z
Cornell Law Rev; 2014 Jul; 99(5):1227-58. PubMed ID: 25112001
[No Abstract] [Full Text] [Related]
7. An economic assessment of patent settlements in the pharmaceutical industry.
Dickey B; Orszag J; Tyson L
Ann Health Law; 2010; 19(2):367-400, 2 p preceding i. PubMed ID: 21443148
[TBL] [Abstract][Full Text] [Related]
8. Bib Pharma Monopoly: Why Consumers Keep Landing on "Park Place" and How the Game is Rigged.
Levy MS
Am Univ Law Rev; 2016; 66(1):247-303. PubMed ID: 28225582
[TBL] [Abstract][Full Text] [Related]
9. Federal Trade Commission Actions on Prescription Drugs, 2000-2022.
Daval CJR; Egilman AC; Sarpatwari A; Kesselheim AS
JAMA; 2024 Jun; 331(23):2029-2036. PubMed ID: 38767878
[TBL] [Abstract][Full Text] [Related]
10. Settlements between brand and generic pharmaceutical companies: a reasonable antitrust analysis of reverse payments.
Yvon AM
Fordham Law Rev; 2006 Dec; 75(3):1883-912. PubMed ID: 17312596
[No Abstract] [Full Text] [Related]
11. Brand-name drug manufacturers risk antitrust violations by slowing generic production through patent layering.
Paine CS
Seton Hall Law Rev; 2003; 33(2):479-510. PubMed ID: 12715807
[No Abstract] [Full Text] [Related]
12. Competition policy in patent cases and antitrust.
Sobel G
Adv Genet; 2003; 50():23-64; discussion 507-10. PubMed ID: 14714685
[TBL] [Abstract][Full Text] [Related]
13. "Pay for delay" settlements of disputes over pharmaceutical patents.
Kesselheim AS; Murtagh L; Mello MM
N Engl J Med; 2011 Oct; 365(15):1439-45. PubMed ID: 21916635
[No Abstract] [Full Text] [Related]
14. Championing consumers. Leibowitz talks of challenging patent agreements, role of antitrust enforcement. Interview by Joe Carlson.
Leibowitz J
Mod Healthc; 2013 Feb; 43(6):18-9. PubMed ID: 23487902
[No Abstract] [Full Text] [Related]
15. The FTC v. Actavis roadmap: a guide to properly applying the rule of reason standard in reverse payment cases.
Sharkey N
J Leg Med; 2014; 35(3):445-66. PubMed ID: 25207633
[No Abstract] [Full Text] [Related]
16. On access and accountability--two Supreme Court rulings on generic drugs.
Boumil MM; Curfman GD
N Engl J Med; 2013 Aug; 369(8):696-7. PubMed ID: 23923990
[No Abstract] [Full Text] [Related]
17. Antitrust: medical device corporation liable for violating FTC order.
Montgomery R
J Law Med Ethics; 2002; 30(1):122-3. PubMed ID: 11905263
[No Abstract] [Full Text] [Related]
18. Battle not over: FTC wants Supreme Court to review Palmyra case.
Carlson J
Mod Healthc; 2012 Mar; 42(10):8-9. PubMed ID: 22458067
[No Abstract] [Full Text] [Related]
19. Physician organizations: two years under the FTC/DOJ guidelines.
Enders RJ
Health Care Law Newsl; 1995 Oct; 10(10):9-11. PubMed ID: 10151244
[TBL] [Abstract][Full Text] [Related]
20. Avoiding antitrust compliance difficulties in mergers and acquisitions.
Bryant LE
Healthc Financ Manage; 1993 Aug; 47(8):48-50, 52, 54-8. PubMed ID: 10145853
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
